Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LTP · 1 trial · 1 indication
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations and adverse events up to and including the end-of-study visit.
PVR is a hemodynamic variable of pulmonary circulation and is measured by right heart catheterization.
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations, treatment-emergent adverse events and discontinuations due to adverse events.
| Arm | Type | Description |
|---|---|---|
| LTP001 Dose 1 | EXPERIMENTAL | - |
| LTP001 Dose 2 | EXPERIMENTAL | - |
| LTP001 Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | matching placebo |
| Name | Type | Description |
|---|---|---|
| LTP | DRUG | LTP001 |
| Placebo | DRUG | Placebo |
Part A Inclusion Criteria: * Healthy males and non-child-bearing potential females Part A Exclusion Criteria: * Clinically significant ECG or cardiac abnormalities, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, o...
LTP is an investigational small molecule being studied for the treatment of Pulmonary Arterial Hypertension (PAH) and is also evaluated in healthy volunteers. It is currently in Phase 1 clinical development, with a single active trial recruiting participants in multiple countries.
LTP is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy participants and in participants with Pulmonary Arterial Hypertension.
LTP is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The current trial is recruiting participants to assess the treatment in healthy volunteers and in patients with Pulmonary Arterial Hypertension.
LTP is being studied in a single Phase 1 clinical trial with the identifier NCT06649110. The trial is titled 'A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)' and is currently recruiting 232 participants across multiple countries.
Yes, LTP is being studied in healthy volunteers as part of a Phase 1 clinical trial. The trial includes a Part A in healthy participants and a Part B in participants with Pulmonary Arterial Hypertension. The study is randomized, double-blind, and placebo-controlled, with a total enrollment of 232 participants.